|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 409 12th Street, SW |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
|
5. Senate ID# 400578740-12
|
||||||||
|
6. House ID# 412490000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kira Peterson |
Date | 4/20/2026 3:37:31 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Womens health research (general); Centers for Disease Control and Prevention (CDC); CDC Office on Smoking and Health; National Institutes of Health (NIH); NIH workforce training programs; National Center for Health Statistics; Agency for Healthcare Research and Quality (AHRQ); NIH Office of Research on Womens Health; Health Resources and Services Administration (HRSA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Safe Motherhood and Infant Health Program (CDC); National Center for Chronic Disease Prevention and Health Promotion (CDC); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC); inclusion of pregnant and lactating people in clinical trials (general); Congressionally Directed Medical Research Program (CDMRP); bladder cancer research through CDMRP; Title X family planning program; Title V Maternal and Child Health Block Grant; Title VII Health Professions and Title VIII Nursing Workforce Development programs; Pregnancy Risk Assessment Monitoring System (CDC); Teaching Health Center Graduate Medical Education Program (THCGME); Healthy Start; National Maternal Mental Health Hotline; maternal mental health programs; Alliance for Innovation on Maternal Health (AIM); stillbirth prevention; Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET); Public Health Data Modernization; implementation of the Dr. Lorna Breen Health Care Provider Protection Act; implementation of the PREEMIE Act; restriction on use of funds for a national unique patient health identifier standard; firearm injury and prevention research; menopause education; Building Interdisciplinary Research Careers in Women's Health (BIRCWH); Womens Reproductive Health Research (WRHR)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
FY27 National Defense Authorization Act; H.R. 6797, IVF for Military Families Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Sarah |
Bogdan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. _____/S. _____, Advancing Safe Medications for Moms and Babies Act; Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of labor and delivery units in rural hospitals on patient access to care and maternal morbidity and mortality; abortion training in obstetrics and gynecology residency programs (general); Teaching Health Center Graduate Medication Education program (general); P.L. 119-21, One Big, Beautiful Bill Act; H.R. 1909/S. 2621, Preventing Maternal Deaths Reauthorization Act of 2025; Telemedicine (general); S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 1834/H.R. 3762, Supporting Healthy Moms and Babies Act; H H.R. 7973, Momnibus Act; H.R. 7830, WELLS Act; S. 2433, Neonatal Care Transparency Act; S. 3698/H.R. 7227, Mental Health and MAMA Act; H.R. 6468, Rural Residency Planning and Development Act of 2025; H.R.8159, Gynecologic Pain Management Study Act; H.R.8160, Premenstrual Dysphoric Disorder Awareness and Research Act; H.R.7733, Ensuring OB-GYN Care In Prisons Act; H.R.7148, Consolidated Appropriations Act of 2026; S. Res. 590, Maternal Health Awareness Day Resolution; H.R. ____, Prepregnancy Healthcare Awareness Act; H.R. 7841, Warrior Infertility Act; Toxic Substances Control Act (TSCA); maternal mortality review committees (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Insurance coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); childhood vaccine recommendations (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); NIH/NICHD womens health research (general); access to fertility services and treatments (general); Restorative Reproductive Medicine (general); funding for providers of reproductive health care (general); prepregnancy health (general); Affordable Care Act (general); Advisory Committee on Immunization Practices (ACIP); COVID vaccine during pregnancy (general); S.____, Maternal Health Pandemic Response Act; United States Preventive Services Taskforce (general); hormone therapy for menopause symptoms (general); acetaminophen use during pregnancy (general); SSRI use during pregnancy (general); Pregnancy Risk Assessment Monitoring System (PRAMS); Maternal Mortality Review Information Application (MMRIA); Maternity Care Target Areas proposed updates; Emergency Medical Treatment and Active Labor Act (EMTALA)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Treatment of pregnant and postpartum people in immigration detention (general); access to medical care in immigration detention (general); H.R. 1061/S. 455, Protecting Sensitive Locations Act; H-1B visa petition fees
17. House(s) of Congress and Federal agencies Check if None
Homeland Security - Dept of (DHS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Sarah |
Bogdan |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Physician payment under Medicare (general); Medicare Physician Fee Schedule Efficiency Adjustment (general); Graduate medical education (general); S.1816/H.R. 3514, Improving Seniors Timely Access to Care Act of 2025; Prior authorization in Medicare (general); Medicaid (general); Medicaid work requirements (general); CMS billing and coding procedures (general); preserving postpartum Medicaid extension (general); P.L. 119-21, One Big, Beautiful Bill Act; telehealth (general); H.R. 7520, Efficiency Adjustment Delay Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Taylor |
Platt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Department of Education proposed changes to Definition of Professional Degrees
17. House(s) of Congress and Federal agencies Check if None
Education - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sarah |
Bogdan |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |